Department of Gastroenterological Surgery, Gastroenterological Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Ann Surg Oncol. 2017 Aug;24(8):2233-2240. doi: 10.1245/s10434-017-5828-0. Epub 2017 Mar 9.
Laparoscopic pylorus-preserving gastrectomy (LPPG) has been introduced as a minimally invasive function-preserving operation for early gastric cancer (GC). This study aimed to investigate the surgical and prognostic outcomes after LPPG at the authors' institution.
This study analyzed 465 patients who underwent LPPG for cT1 N0 GC located in the middle part of the stomach between 2006 and 2012. Short- and long-term surgical outcomes including 5-year survival rates, postoperative nutritional data, and body weight change were retrospectively investigated.
Regarding short-term surgical results, 14 (3%) of the 465 patients had severe complications classified as Clavien-Dindo grade 3a or above, and no mortality occurred (no in-hospital deaths). The median follow-up period was 1829 days (range 226-3197 days), and the 5-year overall survival and relapse-free survival rates were respectively 98% (95% confidence interval [CI] 96.1-99.0%) and 98% (95% CI 96.1-99.0%). Only two cases of postoperative recurrence were confirmed, and their recurrence sites were not in the remnant stomach or regional lymph nodes. The postoperative nutritional status, in terms of serum total protein, albumin, and hemoglobin levels, was well maintained, and the mean relative body weight (postoperative/preoperative) was 93.24 ± 7.29% after LPPG.
For the first time, we have clarified the detailed long-term survival outcomes of LPPG for cT1 N0 GC. LPPG is an acceptable and favorable operative method for clinically diagnosed early-stage GC, in terms of long-term survival and postoperative nutrition.
腹腔镜保留幽门胃切除术(LPPG)已作为一种微创保功能手术应用于早期胃癌(GC)。本研究旨在探讨作者所在机构行 LPPG 的手术和预后结果。
本研究分析了 2006 年至 2012 年间在胃中部接受 LPPG 治疗的 465 例 cT1N0 GC 患者。回顾性调查了短期和长期手术结果,包括 5 年生存率、术后营养数据和体重变化。
在短期手术结果方面,465 例患者中,有 14 例(3%)发生严重并发症,分类为 Clavien-Dindo 分级 3a 或以上,无死亡(无院内死亡)。中位随访时间为 1829 天(范围 226-3197 天),5 年总生存率和无复发生存率分别为 98%(95%可信区间 96.1-99.0%)和 98%(95%可信区间 96.1-99.0%)。仅确认了 2 例术后复发,其复发部位不在残胃或区域淋巴结。术后营养状态,血清总蛋白、白蛋白和血红蛋白水平良好,LPPG 后平均相对体重(术后/术前)为 93.24±7.29%。
我们首次明确了 LPPG 治疗 cT1N0 GC 的详细长期生存结果。就长期生存和术后营养而言,LPPG 是一种可接受且有利的早期 GC 临床诊断手术方法。